Renal function with use of a tenofovir-containing initial antiretroviral regimen
about
Epidemiology, clinical characteristics, and management of chronic kidney disease in human immunodeficiency virus-infected patientsRenal function in Ghanaian HIV-infected patients on highly active antiretroviral therapy: a case-control studyWeek 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patientsPrevalence and factors associated with renal dysfunction among HIV-infected patientsEffect of changing from first- to second-line antiretroviral therapy on renal function: a retrospective study based on data from a single health facility in Namibia.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Effects of switching from efavirenz to raltegravir on endothelial function, bone mineral metabolism, inflammation, and renal function: a randomized, controlled trial.Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapyRenal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitorsZidovudine and Lamivudine for HIV Infection.Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapineThe New Epidemiology of HIV-Related Kidney Disease.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Recent developments in HIV-related kidney disease.Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study.Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trialWHO antiretroviral therapy guidelines 2010 and impact of tenofovir on chronic kidney disease in Vietnamese HIV-infected patients.A consensus statement on the renal monitoring of Australian patients receiving tenofovir based antiviral therapy for HIV/HBV infection.Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?HAART, DOTS and renal disease of patients co-infected with HIV/AIDS and TB in the South West Region of Cameroon.Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.The Incidence and Clinical Characteristics of Acute Serum Creatinine Elevation more than 1.5 mg/dL among the Patients Treated with Tenofovir/Emtricitabine-containing HAART RegimensRisk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care.Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir.Antiretroviral-treated HIV-infected women have similar long-term kidney function trajectories as HIV-uninfected women.Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.Antiretroviral therapy-induced changes in plasma lipids and the risk of kidney dysfunction in HIV-infected menManagement of HIV and hepatitis virus coinfection.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Renal issues in HIV infection.How to manage HIV-infected patients with chronic kidney disease in the HAART era.Renal toxicity associated with antiretroviral therapy.Update on tenofovir toxicity in the kidney.Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.Ageing with HIV: a multidisciplinary review.
P2860
Q27009523-383DD012-0E7F-4346-9725-509C89FE17B7Q28539647-9DE0CBC9-2181-4F99-9C6D-0EA1C06F53B1Q28545183-2EE0B697-57D8-4E69-AA63-2A5BED394765Q30484533-9904012D-1747-43D8-93DD-C8CD624A640FQ31108490-3306FAED-6519-4628-B8DE-3B9814924241Q33775397-7504D107-42D6-4F94-B09E-94D99EEDF9B2Q33880418-A20172AC-77A5-43DB-8A36-36DFDB936F6AQ33939760-5CDC2D7A-D404-46FA-9F0B-B47A5233653AQ34126724-2D3BB6F6-015B-441C-B635-598D38A06FBDQ34136166-4E12C9C0-B92A-4008-8843-C021DD1AC747Q34194561-9E228F83-0660-420E-B7F1-BD75AAB53E7CQ34250879-2A916DA6-27BD-4C3C-AF15-53170EB6EA2DQ34307868-8B4F5E4A-293B-4491-AB6C-0F2C041EC848Q34478840-3F13C055-5D10-42D8-88E4-DD439C058EDEQ34536677-283831A5-9546-421C-8BA9-A0CC8AC192BBQ34572458-A382F814-67C1-4A14-97AF-DCCD11AC616AQ34686870-7C8FD25A-C751-4E56-9991-37B3B1A2D0EBQ34736194-42DF0317-7BC5-4951-950E-F7620ED50CEBQ34787977-7373683D-0035-4EFF-A509-6C6491D4B6B6Q34952127-E3D9501D-AFA4-47FF-8CF4-903D630F3E07Q35040358-23645957-B940-4E1D-8835-691BF41BA5AFQ35149475-1BCE43CE-479F-466E-8737-75E19060BBF5Q35170350-1045A71F-5F07-4DEC-AB38-DEF619C7F3ACQ35770848-C0998542-2500-4042-80F8-78EA7A038D59Q35802060-DBB8371A-1577-411E-B51F-F91675A28B30Q36198650-0E626E7A-A861-43BE-B2D0-BD5CB2759F83Q36472367-0E85ED6C-967E-4959-9214-063DC7E97C68Q36492436-5F49E380-F98D-4FDF-BC98-DF37285A91EFQ36651106-0264F2B6-E771-4D9E-91F9-F615735F692FQ36795839-C23504E1-91CC-4C9D-A591-FBA7EADE1C9AQ36988748-6B89C2D9-FFA7-44ED-9E24-27AAD9383205Q37204118-D622AB69-2673-40AD-B37A-E3FF477C6E40Q37772508-9D1E0198-283E-40EA-938B-1355238C2866Q37835819-6C1E1044-A0D4-472D-85C7-534075D40FA3Q37885232-F4B2539F-0353-4A04-A18E-7327D23ABBA9Q37980388-39F34F2E-6312-4084-8C7D-BB56E0DFE0F0Q38031028-EB4D45B3-70DC-424D-9D3B-AD2067D4149DQ38033446-193F7A39-0EFE-45AF-9799-9CD3BA2CB62BQ38222708-C1854FDE-EF0E-4BD8-9DE8-E40B5B7DDBFEQ38490362-864CB998-8E34-4F94-8814-DA956A06F1EA
P2860
Renal function with use of a tenofovir-containing initial antiretroviral regimen
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Renal function with use of a tenofovir-containing initial antiretroviral regimen
@en
Renal function with use of a tenofovir-containing initial antiretroviral regimen.
@nl
type
label
Renal function with use of a tenofovir-containing initial antiretroviral regimen
@en
Renal function with use of a tenofovir-containing initial antiretroviral regimen.
@nl
prefLabel
Renal function with use of a tenofovir-containing initial antiretroviral regimen
@en
Renal function with use of a tenofovir-containing initial antiretroviral regimen.
@nl
P2860
P1433
P1476
Renal function with use of a tenofovir-containing initial antiretroviral regimen
@en
P2093
Joel E Gallant
Richard D Moore
P2860
P304
P356
10.1097/QAD.0B013E32832C96E9
P407
P577
2009-09-01T00:00:00Z